Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 20 of 39, showing 5 Applications out of 192 total, starting on record 96, ending on 100

# Protocol No Study Title Investigator(s) & Site(s)

96.

ECCT/21/08/01   CARES
    Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa.   
Principal Investigator(s)
1. JOSPHAT KOSGEI
Site(s) in Kenya
1. AMPATH Eldoret (Uasin Gishu county)
2. Aghakhan University (Nairobi City county)
3. Kericho KEMRI WRP CRC site (Kericho county)
 
View

97.

ECCT/21/09/08   GBT133_Inclacumab Open-Label
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Bernhards Ragama Ogutu
3. Videlis N Nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
View

98.

ECCT/21/07/05   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa       
Principal Investigator(s)
1. Dr Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. KEMRI Walter Reed Project (Kericho county)
3. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

99.

ECCT/21/07/06   GBT132_Inclacumab-Ps 3 Trial
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Fredrick Asirwa Chite
2. Videlis N Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Strathmore University Medical Centre (Nairobi City county)
 
View

100.

ECCT/21/09/01   Kuwa Free! - Live free!
    Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives   
Principal Investigator(s)
1. Rena Patel
2. Edwin Were
Site(s) in Kenya
Moi Teaching and Referral Hospital
 
View